Tellgen(SZ:300642) Sou Hu Cai Jing·2025-07-09 09:40Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 15.24 yuan with a PE ratio of 62.73, marking a new low in 75 days, and a total market capitalization of 2.477 billion yuan [1] - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing Tongjing Life at the 92nd position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Tongjing Life is 17,040, a decrease of 590 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tongjing Life focuses on the research, production, and sales of in vitro diagnostic products under its own brand, with major products including diagnostic reagents, instruments, and service income [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1] - In the latest quarterly report for Q1 2025, Tongjing Life reported an operating revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, and a net profit of 471,700 yuan, a year-on-year increase of 110.51%, with a gross profit margin of 63.66% [1]